Bristol Rebuilds Oncology Business: Smart Work at FDA Helps

Bristol-Myers Squibb's oncology franchise is at roughly 70% of its level before Taxol went generic and sales began to freefall. But with a couple of recent product launches, expanding indications for others, and a showing that it can naviigate FDA in spaces where competitors have stumbled, it is back on track again.